JP2000512652A - 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途 - Google Patents
腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途Info
- Publication number
- JP2000512652A JP2000512652A JP10502317A JP50231798A JP2000512652A JP 2000512652 A JP2000512652 A JP 2000512652A JP 10502317 A JP10502317 A JP 10502317A JP 50231798 A JP50231798 A JP 50231798A JP 2000512652 A JP2000512652 A JP 2000512652A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- hydroxy
- group
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19624668A DE19624668A1 (de) | 1996-06-20 | 1996-06-20 | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| DE19624668.7 | 1996-06-20 | ||
| PCT/EP1997/003244 WO1997048397A1 (en) | 1996-06-20 | 1997-06-20 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000512652A true JP2000512652A (ja) | 2000-09-26 |
| JP2000512652A5 JP2000512652A5 (2) | 2005-02-10 |
Family
ID=7797502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10502317A Withdrawn JP2000512652A (ja) | 1996-06-20 | 1997-06-20 | 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0912176B1 (2) |
| JP (1) | JP2000512652A (2) |
| AT (1) | ATE224713T1 (2) |
| AU (1) | AU3262497A (2) |
| DE (2) | DE19624668A1 (2) |
| DK (1) | DK0912176T3 (2) |
| ES (1) | ES2181006T3 (2) |
| PT (1) | PT912176E (2) |
| WO (1) | WO1997048397A1 (2) |
| ZA (1) | ZA975443B (2) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005528361A (ja) * | 2002-03-27 | 2005-09-22 | フジサワ ドイッチラント ゲーエムベーハー | 脈管形成抑制剤としてのピリジルアミド |
| JP2010507643A (ja) * | 2006-10-27 | 2010-03-11 | リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ | ブラジキニン拮抗剤としての新規フェニルスルファモイルベンズアミド誘導体 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
| US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
| DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
| DE19756212A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
| DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
| DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
| WO2000009132A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
| DE19908483A1 (de) * | 1999-02-26 | 2000-10-05 | Klinge Co Chem Pharm Fab | Inhibitoren der zellulären Niacinamidmononucleotid-Bildung |
| EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
| JP2004507465A (ja) * | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| IL155093A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Morpholin-acetamide derivatives for the treatment on inflammatory diseases |
| GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| JP4521463B2 (ja) * | 2005-03-17 | 2010-08-11 | ファイザー株式会社 | 疼痛の治療に有用なｎ−（ｎ−スルホニルアミノメチル）シクロプロパンカルボキサミド誘導体 |
| PE20071159A1 (es) | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
| WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| RU2529468C2 (ru) | 2008-06-24 | 2014-09-27 | Топотаргет А/С | Производные 1, 2-дигидроциклобутендиона в качестве ингибиторов фосфорибозилтрансферазы никотинамида |
| JP5688367B2 (ja) | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ | 新規なウレアおよびチオウレア誘導体 |
| CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| JP6038792B2 (ja) | 2010-09-03 | 2016-12-07 | フォーマ ティーエム， エルエルシー． | 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体 |
| CN106243023A (zh) | 2010-09-03 | 2016-12-21 | 福马Tm有限责任公司 | 用于抑制nampt的胍化合物和组合物 |
| PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
| KR101916481B1 (ko) * | 2010-09-29 | 2018-11-07 | 인터벳 인터내셔널 비.브이. | Ｎ-헤테로아릴 화합물 |
| AU2011329233A1 (en) | 2010-11-15 | 2013-05-23 | Abbvie Deutschland Gmbh & Co Kg | NAMPT and ROCK inhibitors |
| EP2640704A1 (en) | 2010-11-15 | 2013-09-25 | Abbvie Inc. | Nampt inhibitors |
| RU2017112522A (ru) | 2011-05-04 | 2019-01-24 | ФОРМА ТиЭм, ЭлЭлСИ | Новые соединения и композиции для ингибирования nampt |
| WO2012154194A1 (en) | 2011-05-09 | 2012-11-15 | Forma Tm, Llc | Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt) |
| US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
| AR091022A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| MX2014013758A (es) | 2012-05-11 | 2015-02-05 | Abbvie Inc | Derivados de tiazolcarboxamida para usarse como inhibidores de nampt. |
| CA2873075A1 (en) | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
| WO2014085607A1 (en) | 2012-11-29 | 2014-06-05 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
| EP3016946B1 (en) | 2013-07-03 | 2022-10-12 | Karyopharm Therapeutics Inc. | Substituted benzofuranyl and benzoxazolyl compounds and pharmaceutical uses thereof |
| WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
| HK1255438A1 (zh) | 2015-08-18 | 2019-08-16 | 卡尔约药物治疗公司 | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |
| WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
| TWI835714B (zh) | 2016-10-18 | 2024-03-21 | 美商思進公司 | 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞 |
| WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
| WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
| JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ） |
| KR102831570B1 (ko) | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| AU2020378067A1 (en) | 2019-11-06 | 2022-05-26 | Remedy Plan, Inc. | Cancer treatments targeting cancer stem cells |
| JP2024518089A (ja) | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
| EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
| US5352684A (en) * | 1990-04-10 | 1994-10-04 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridines as medicaments |
| WO1991015485A1 (de) * | 1990-04-10 | 1991-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridinester |
-
1996
- 1996-06-20 DE DE19624668A patent/DE19624668A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705443A patent/ZA975443B/xx unknown
- 1997-06-20 AT AT97928260T patent/ATE224713T1/de active
- 1997-06-20 JP JP10502317A patent/JP2000512652A/ja not_active Withdrawn
- 1997-06-20 EP EP97928260A patent/EP0912176B1/en not_active Expired - Lifetime
- 1997-06-20 PT PT97928260T patent/PT912176E/pt unknown
- 1997-06-20 WO PCT/EP1997/003244 patent/WO1997048397A1/en not_active Ceased
- 1997-06-20 DE DE69715861T patent/DE69715861T2/de not_active Expired - Lifetime
- 1997-06-20 AU AU32624/97A patent/AU3262497A/en not_active Abandoned
- 1997-06-20 DK DK97928260T patent/DK0912176T3/da active
- 1997-06-20 ES ES97928260T patent/ES2181006T3/es not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005528361A (ja) * | 2002-03-27 | 2005-09-22 | フジサワ ドイッチラント ゲーエムベーハー | 脈管形成抑制剤としてのピリジルアミド |
| JP2010507643A (ja) * | 2006-10-27 | 2010-03-11 | リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ | ブラジキニン拮抗剤としての新規フェニルスルファモイルベンズアミド誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE224713T1 (de) | 2002-10-15 |
| ZA975443B (en) | 1998-02-10 |
| EP0912176B1 (en) | 2002-09-25 |
| DE69715861D1 (de) | 2002-10-31 |
| ES2181006T3 (es) | 2003-02-16 |
| WO1997048397A1 (en) | 1997-12-24 |
| AU3262497A (en) | 1998-01-07 |
| DE69715861T2 (de) | 2003-06-12 |
| DK0912176T3 (da) | 2003-01-13 |
| EP0912176A1 (en) | 1999-05-06 |
| DE19624668A1 (de) | 1998-02-19 |
| PT912176E (pt) | 2003-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000512652A (ja) | 腫瘍の治療または免疫抑制におけるピリジルアルカン、ピリジルアルケンおよび／またはピリジルアルキン酸アミド類の用途 | |
| JP4225572B2 (ja) | 細胞増殖抑制剤および免疫抑制剤としてのピリジルアルケン―およびピリジルアルキン―酸アミド類 | |
| JP4855576B2 (ja) | ピペラジニル−置換ピリジルアルカン、アルケンおよびアルキンカルボキサミド類 | |
| JP4570247B2 (ja) | 新規なピペリジニル−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類 | |
| JP4225571B2 (ja) | 細胞増殖抑制剤および免疫抑制剤としての新規なピリジルアルカン酸アミド類 | |
| US6903118B1 (en) | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides | |
| JP4838934B2 (ja) | 細胞増殖抑制剤及び免疫抑制剤として有用なアリール−置換ピリジルアルカン、アルケン及びアルキンカルボキサミド類 | |
| KR100478405B1 (ko) | 세포분열억제제및면역억제제로서의피리딜알켄-및피리딜알킨-산아미드 | |
| HK1021974B (en) | Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040608 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040608 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070322 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080115 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080416 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20080617 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080917 |